Survodutide vs Tirzepatide: Research Comparison
A Side-By-Side Research Comparison Of Survodutide And Tirzepatide - a glucagon/GLP-1 dual agonist versus a GIP/GLP-1 dual agonist in metabolic research. This Reference Compares Mechanism, Evidence Tier, Molecular Identity, And Pharmacokinetics For Qualified Researchers. For In Vitro Laboratory Research Use Only. Not Medical Advice Or Dosing Guidance.
Side-By-Side Comparison
| Survodutide | Tirzepatide | |
|---|---|---|
| Category | Weight Loss & Metabolism | Weight Loss & Metabolism |
| Compound Class | Synthetic dual agonist: GLP-1 receptor + glucagon receptor | Dual GIP/GLP-1 receptor co-agonist (twincretin); synthetic 39-residue peptide with C18 fatty diacid for albumin binding |
| Evidence Tier | Investigational | Approved Drug |
| Molecular Target | GLP-1R (satiety, insulin secretion) + GCGR (glucagon receptor: energy expenditure, hepatic lipid metabolism); dual incretin-glucagon signaling | GIPR (GIP receptor) + GLP-1R (GLP-1 receptor); dual incretin axis activation; pancreatic insulin secretion and hypothalamic appetite suppression |
| Molecular Weight | 4231.63 Da | 4813.45 Da |
| Amino Acid Sequence | GLP-1/glucagon dual agonist (acylated synthetic peptide) | 39-aa acylated peptide (C20 diacid) |
| CAS Number | 2805997-46-8 | 2023788-19-2 |
| Half-Life | ~1 week | ~1 week |
| Studied For | Obesity / overweight, Type 2 diabetes, MASH / metabolic liver disease, Non-alcoholic steatohepatitis (NASH) | Type 2 diabetes management, Chronic weight management / obesity, Obstructive sleep apnea in obesity (FDA approved 2024), Non-alcoholic fatty liver disease (NAFLD/MASH) |
About Survodutide
An investigational dual-agonist weight-loss and liver-disease peptide.
Read The Full Survodutide MonographAbout Tirzepatide
The approved dual-incretin weight-loss and diabetes drug; compounded versions are not FDA-evaluated.
Read The Full Tirzepatide MonographKey Differences
- Evidence tier differs: Survodutide is classified as Investigational; Tirzepatide is classified as Approved Drug.
- Primary molecular target differs: Survodutide acts on GLP-1R (satiety, insulin secretion) + GCGR (glucagon receptor: energy expenditure, hepatic lipid metabolism); dual incretin-glucagon signaling; Tirzepatide acts on GIPR (GIP receptor) + GLP-1R (GLP-1 receptor); dual incretin axis activation; pancreatic insulin secretion and hypothalamic appetite suppression.
Continue Researching
This Comparison Is Provided For In Vitro Laboratory Research Use Only. Not For Human Consumption, Diagnosis, Or Treatment. See The Full Research Disclaimer.